Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Nimotuzumab Combined with Chemotherapy as Second- or Later-line  in the Treatment of Advanced Lung Squamous Cell Carcinoma].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Oct 2016

Luo Yang, Li Junling, Wang Yan, Hao Xuezhi, Qu Fenglian

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) is commonly overexpressed in lung squamous cell carcinoma and has been associated with impaired prognosis. The aim of this study was to observe the efficacy and safety of nimotuzumab, a anti-EGFR monoclonal antibody, combined with chemotherapy as second- or later-line in the treatment of advanced lung squamous cell carcinoma. METHODS: A retrospective analysis of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasm Staging

Source

Open in PubMed Open full text

Identifiers

PMID: 27760595
DOI: 10.3779/j.issn.1009-3419.2016.10.05
PMCID: PMC5973415

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Nimotuzumab Combined with Chemotherapy as Second- or Later-line in the Treatment of Advanced Lung Squamous Cell Carcinoma].PMID 27760595Read ↗

[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Semantic proximity Read ↗

[Treatment of Advanced Squamous Cell Lung Cancer].Semantic proximity Read ↗

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study.Semantic proximity Read ↗

Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.Semantic proximity Read ↗

[Association between the epidermal growth receptor status and the efficacy of first-line chemotherapy in patients with advanced non-small cell lung cancer].Semantic proximity Read ↗

[Efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy as first-line treatment for epidermal growth factor receptor-mutant advanced non-small cell lung cancer].Semantic proximity Read ↗

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.Semantic proximity Read ↗

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.Semantic proximity Read ↗

Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).Semantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).Semantic proximity Read ↗

[Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.